Author

admin

Browsing

1911 Gold Corporation (TSXV: AUMB,OTC:AUMBF) (OTCQB: AUMF) (FSE: 2KY) (‘1911 Gold’ or the ‘Company’) is pleased to announce that it will be participating in the 51st Annual New Orleans Investment Conference at the Hilton New Orleans Riverside November 2 – 5, 2025. Shaun Heinrichs, President & CEO, will be presenting on Wednesday, November 5th, and is looking forward to networking with investors during the Conference.

The New Orleans Investment Conference gathers some of the world’s brightest and most successful analysts, newsletter writers and investors. This year’s event will highlight all major asset classes, including Gold.

Don’t miss out. Register for the 51st Annual New Orleans Investment Conference by clicking here.

About 1911 Gold Corporation

1911 Gold is a junior developer with a highly prospective, consolidated land package totaling more than 61,647 hectares within and adjacent to the Archean Rice Lake greenstone belt in Manitoba, Canada. The Company also owns the True North mine and mill complex in Bissett, Manitoba. 1911 Gold believes its land package represents a prime exploration opportunity, with the potential to develop a mining district centred on the True North complex.

In addition, the Company holds the Apex project near Snow Lake, Manitoba and the Denton-Keefer project near Timmins, Ontario, and remains focused on advancing organic growth while pursuing accretive acquisition opportunities across North America.

1911 Gold’s True North complex is located within the traditional territory of the Hollow Water First Nation, signatory to Treaty No. 5 (1875-76). 1911 Gold looks forward to maintaining open, co-operative and respectful communication with the Hollow Water First Nation, and all local stakeholders, in order to build mutually beneficial working relationships.

About The New Orleans Investment Conference

The New Orleans Investment Conference is the one place where the world’s most sophisticated investors gather every year to discover new opportunities and strategies, exchange ideas, plan for the coming year and enjoy the camaraderie of like-minded individuals in America’s most fascinating and entertaining city.

Headliners at the New Orleans Conference over the last 50 years have included Lady Margaret Thatcher, former President Gerald Ford, novelist Ayn Rand, General H. Norman Schwarzkopf, Nobel Prize-winning economists Milton Friedman and F.A. Hayek, Dr. Henry Kissinger, Senator Barry Goldwater, Admiral Hyman Rickover, Louis Rukeyser, Sir John Templeton, Lord William Rees-Mogg, Charlton Heston, Jeane Kirkpatrick, Robert Bleiberg, Jack Kemp, William F. Buckley, General Colin Powell, Ron Paul and J. Peter Grace, among hundreds of other notables.

ON BEHALF OF THE BOARD OF DIRECTORS

Shaun Heinrichs
President and CEO

For further information, please contact:

Shaun Heinrichs
Chief Executive Officer

(604) 674-1293
ir@1911gold.com

www.1911gold.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/271734

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com

The AIER Everyday Price Index (EPI) rose 0.29 percent to 297.6 in September 2025, marking its tenth consecutive monthly increase and bringing the year-to-date change to roughly 3.2 percent. Out of the 24 components, 15 categories posted price increases, one was unchanged, and eight declined. The strongest gains came from gardening and lawncare services, motor fuel, and intracity transportation, reflecting both seasonal and energy-related pressures. Offsetting those, the most notable price declines occurred in nonprescription drugs, admissions to movies, theaters, and concerts, and housing fuels and utilities, indicating modest relief in select consumer essentials.

AIER Everyday Price Index vs. US Consumer Price Index (NSA, 1987 = 100)

(Source: Bloomberg Finance, LP)

Also on October 24, 2025, the US Bureau of Labor Statistics (BLS) released its September 2025 Consumer Price Index (CPI) data. The month-to-month headline CPI rose 0.3 percent while the core month-to-month CPI number increased by 0.2 percent, both of which were lower than forecasts by 0.1 percent.

September 2025 US CPI headline and core month-over-month (2015 – present)

(Source: Bloomberg Finance, LP)

In September 2025, the food index rose 0.2 percent following a 0.5 percent increase in August, with food at home prices climbing 0.3 percent as four of six major grocery categories posted gains, including other food at home (0.5 percent), cereals and bakery products (0.7 percent), nonalcoholic beverages (0.7 percent), and meats, poultry, fish, and eggs (0.3 percent), while dairy products declined 0.5 percent and fruits and vegetables remained unchanged, and food away from home increased a modest 0.1 percent. Energy costs surged 1.5 percent in September, accelerating from August’s 0.7 percent rise, driven primarily by gasoline prices that jumped 4.1 percent, while electricity fell 0.5 percent and natural gas dropped 1.2 percent. 

Core inflation, excluding food and energy, moderated to 0.2 percent in September from 0.3 percent in each of the previous two months, with shelter costs rising 0.2 percent as owners’ equivalent rent posted its smallest monthly gain (0.1 percent) since January 2021. 

Also in the core numbers, transportation costs were mixed, with airline fares increasing 2.7 percent and new vehicles rising 0.2 percent as motor vehicle insurance and used cars and trucks both declined 0.4 percent. Other notable changes included recreation and household furnishings each rising 0.4 percent, apparel gaining 0.7 percent, personal care up 0.4 percent, and communication falling 0.2 percent. Medical care costs increased 0.2 percent overall, with hospital services and prescription drugs each rising 0.3 percent, offsetting declines in dental services (down 0.6 percent), and physicians’ services (down 0.1 percent).

Tracking changes over the previous 12 months, both the headline and core Consumer Price Indices rose 3.1 percent, slightly higher than the 3.0 percent rise that was projected for both.

September 2025 US CPI headline and core year-over-year (2015 – present)

(Source: Bloomberg Finance, LP)

Over the 12 months ending in September, overall food prices increased 2.7 percent, with grocery prices holding steady from August while dining-out costs accelerated to a 3.7 percent annual pace. Within food categories, meats, poultry, fish, and eggs climbed 5.2 percent, and nonalcoholic beverages rose 5.3 percent, while “other food at home” advanced 1.9 percent and cereals and bakery goods were up 1.6 percent. Energy prices rose 2.8 percent over the year, led by steep gains in electricity (5.1 percent) and natural gas (11.7 percent), though gasoline edged 0.5 percent lower. Full-service restaurant meals rose 4.2 percent compared with 3.2 percent for limited-service meals, while fruits and vegetables gained 1.3 percent and dairy prices were up a modest 0.7 percent.

Core CPI, which excludes food and energy, increased 3.0 percent year-over-year, driven primarily by shelter costs, which advanced 3.6 percent. Other notable contributors included household furnishings and operations (4.1 percent), used cars and trucks (5.1 percent), medical care (3.3 percent), and recreation (3.0 percent). These figures highlight that while goods inflation has moderated, services and housing remain the key sources of upward price pressure within the core index.

The September 2025’s Consumer Price Index report delivered news of a welcome moderation in inflation, marking the slowest pace of underlying price growth in three months. Core CPI was restrained by a cooling in shelter costs — the smallest increase in owners’ equivalent rent since early 2021. Broader price movements were similarly tame: goods inflation eased on cheaper used cars and slower gains in household furnishings, while services inflation was capped by softening rents and airfare costs. Of note, the data release was delayed by the ongoing federal shutdown and assembled primarily to ensure the Social Security Administration could calculate its 2.8 percent cost-of-living adjustment for next year.

For policymakers at the Federal Reserve, the report reinforces confidence that price pressures are continuing to cool without threatening broader economic stability. The slower pace of inflation, particularly across shelter and core services, effectively seals the case for a 25-basis-point rate cut at the late-October Federal Open Market Committee meeting and strengthens the likelihood of another in December. The immediate financial market reaction reflected that view: Treasury yields, and the dollar slipped, while stock futures advanced. Despite persistent tariff exposure — particularly in categories like apparel and household goods — the overall pass-through to consumers remains modest. Estimates suggest firms passed through roughly 26 cents of every dollar in new tariff costs, underscoring how competitive pressures and slowing demand are muting inflation’s reach.

Still, the data paint a nuanced picture beneath the headline calm. Measures of inflation breadth show that while fewer items posted outsized increases, nearly half of core CPI components continue to rise at an annualized rate above 4 percent, signaling lingering while narrowing stickiness. The primary concern now is not so much inflation’s direction but data continuity: with the government still shuttered, the Bureau of Labor Statistics has suspended most data collection, casting doubt on the release and accuracy of upcoming CPI reports. For the moment, though, September’s figures offer reassurance that inflation is on a slower glide path — enough to justify the Fed’s easing bias but not yet soft enough to rule out renewed vigilance if tariff or supply shocks reemerge over the next several months.

EPI_SEPTEMBER2025_FINALDownload

Trading resumes in:

Company: Quimbaya Gold Inc.

CSE Symbol: QIM

All Issues: Yes

Resumption (ET): 8:15 AM

CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Canadian Investment Regulatory Organization (CIRO) – Halts/Resumptions

Cision View original content: http://www.newswire.ca/en/releases/archive/October2025/24/c1478.html

News Provided by Canada Newswire via QuoteMedia

This post appeared first on investingnews.com

A federal judge struck down a Biden-era rule that expanded federal anti-discrimination measures to transgender healthcare, writing that the Department of Health and Human Services (HHS) ‘exceeded its authority by implementing regulations redefining sex discrimination and prohibiting gender identity discrimination.’

The ruling from Judge Louis Guirola Jr. of the U.S. District Court for the Southern District of Mississippi came after a coalition of 15 Republican-led states sued over the matter, according to The Hill.

‘When Biden-era bureaucrats tried to illegally rewrite our laws to force radical gender ideology into every corner of American healthcare, Tennessee stood strong and stopped them,’ Tennessee Attorney General Jonathan Skrmetti said in a statement following the ruling. ‘Our fifteen-state coalition worked together to protect the right of healthcare providers across America to make decisions based on evidence, reason, and conscience.’

‘This decision restores not just common sense but also constitutional limits on federal overreach, and I am proud of the team of excellent attorneys who fought this through to the finish,’ he added.

Skrmetti’s office said the U.S. District Court for the Southern District of Mississippi held that HHS ‘exceeded its authority when it issued a rule in May 2024 redefining Title IX’s prohibition against discrimination ‘on the basis of sex’ — which Congress incorporated into the ACA through Section 1557 — to include gender identity.’

‘HHS’s 2024 rule represented a disturbing federal intrusion into the States’ traditional authority to regulate healthcare and make decisions about their own Medicaid programs. Specifically, the rule would have prohibited healthcare facilities from maintaining sex-segregated spaces, required certain healthcare providers to administer unproven and risky procedures for gender dysphoria, and forced states to subsidize those experimental treatments through their Medicaid programs,’ it continued. ‘In vacating the rule, Judge Louis Guirola determined that when Congress passed Title IX in 1972, ‘sex’ meant biological sex and that federal agencies cannot unilaterally rewrite laws decades later to advance political agendas.’

The states involved in the lawsuit were Tennessee, Mississippi, Alabama, Georgia, Indiana, Kansas, Kentucky, Louisiana, Nebraska, Ohio, Oklahoma, South Carolina, South Dakota, Virginia, and West Virginia.

The rule was first created under the administration of former President Barack Obama in 2016, before President Donald Trump reversed it in his first term and then former President Joe Biden reversed it again, The Hill reported. 

Guirola’s ruling said HHS ‘exceeded its authority by implementing regulations redefining sex discrimination and prohibiting gender identity discrimination.’ 

The judge vacated the rule universally, but the rule had already been prevented from going into effect. It has been stayed since July 2024, according to Bloomberg Law. 


This post appeared first on FOX NEWS

Imagine a parallel universe where, with the stroke of a pen, President Trump declares an end to the ill-conceived trade war that, while it intensified sharply in April 2025, started in 2017. Not only are the existing duties on steel, aluminum, semiconductors, consumer goods, and countless other imports rescinded, but the administration also explicitly disavows the threat of future tariffs. In an instant, a fog of uncertainty that hangs over the US economy for years vanishes. For thousands of businesses — from family-owned manufacturers in the Midwest to sprawling multinationals with global supply chains — the abrupt shift is transformative.

A New Horizon of Certainty

The first and most immediate effect is psychological: firms that have been paralyzed by uncertainty suddenly see a clear horizon. Projects that sit mothballed — factory expansions, product launches, acquisitions — spring back to life. Capital expenditure budgets, which are padded with contingencies for unpredictable tariff costs, are redirected into tangible investments. CFOs no longer devote boardroom hours to hedging strategies and pricing contingencies; instead, they plan growth with confidence.

Hiring surges. With the removal of tariff-induced costs, margins fatten, and businesses put idle plans into action. A Texas auto-parts maker, once forced to pay a 20 percent surcharge on imported aluminum, now opens a second plant. A Midwestern agricultural-equipment manufacturer that shelves its design for a next-generation harvester rehires engineers to get the project rolling. Technology companies, once squeezed between tariff costs and price-sensitive consumers, accelerate R&D spending and greenlight acquisitions that consolidate their competitive positions.

Supply Chains Realign

Tariffs force many companies to build inefficient, defensive supply chains. Firms reroute imports through third countries or scramble to find suboptimal domestic substitutes. With tariffs gone, supply chains realign on the basis of cost and quality rather than politics. Container traffic through major ports like Long Beach and Savannah spikes, while logistics companies report volumes reminiscent of pre-tariff highs. Freight forwarders, trucking firms, and rail operators all feel the downstream effects of renewed activity.

Inventory positioning sees rapid restrategizing. Where, starting earlier this year, companies stockpiled vast amounts of goods to hedge against possible tariff hikes or retaliatory duties, now they return to leaner, just-in-time models. This frees up working capital for expansion. The elimination of uncertainty — something businesses value almost more than favorable regulation itself — creates efficiencies across the system.

Consumers Regain Confidence

The parallel-universe tariff rollback quickly reverberates through consumer markets. Prices of goods that quietly creep higher — appliances, apparel, electronics — begin to ease. Retailers, once forced to pass higher import costs along to shoppers, now find breathing room to discount and promote. Households, feeling the combined effect of lower prices and rising job opportunities, loosen their wallets. Consumer confidence indexes register sharp upticks, echoing levels not seen in years. A small measure of deflation, the actual decline of prices rather than their deceleration (disinflation), enters the US economy.

Financial markets respond in kind. Equity analysts upgrade earnings forecasts, citing restored margins and reduced input costs. The stock prices of retailers, automakers, and manufacturers jump, while capital-goods and logistics firms trade at premiums reflecting renewed investment. Bond yields rise modestly, reflecting expectations of stronger growth. Even the dollar firms up, as global investors interpret the tariff withdrawal as a sign of restored policy rationality.

Productivity Growth

Beyond the immediate uplift in spending and hiring, the tariff rollback opens the door to longer-term gains. Tariffs function as a tax on productivity: firms spend time and money dodging duties, redesigning supply chains, and lobbying for exemptions rather than innovating. With those distractions gone, resources flow back into efficiency-enhancing investments.

Higher capital expenditures translate into a more modern capital stock: upgraded machinery, cleaner energy systems, better software. The productivity boost that follows is not dramatic in a single quarter, but over time it compounds. Economists projecting GDP growth see their models nudge upward as capital deepening accelerates and labor markets tighten. The virtuous cycle of investment, hiring, and spending reinforces itself.

Global Ripples

The world economy, too, feels the aftershocks. Exporting nations that see their trade with the US fall off — Vietnam, Mexico, Germany, South Korea, and others — suddenly enjoy revitalized access to the world’s largest consumer market. Supply relationships stabilize, and retaliatory tariffs imposed on American goods quietly drop. Farmers, who are squeezed by trade disputes, find foreign demand returning. Energy exports — oil, gas, coal — regain lost markets.

Global institutions like the WTO, which have drifted to the sidelines, are once again treated as forums for dispute resolution rather than ignored. Investor confidence abroad strengthens, and multinational corporations, no longer deterred by the threat of sudden tariffs, expand their US-based operations.

The Parallel Universe Lesson

Of course, this universe is hypothetical. In reality, tariffs remain a prominent feature of American trade policy, and the uncertainty they generate continues to ripple through the economy. But the exercise demonstrates just how powerful a single act of deregulation can be. By eliminating tariffs and withdrawing threats of new ones, the administration sets off a cascade of positive effects: higher investment, faster hiring, stronger growth, and renewed global confidence in US economic leadership.

It is worth stressing that nothing in this parallel universe is beyond reach. The tools required to unleash this growth spurt already exist, sitting unused in the hands of policymakers. With a single declaration, the administration lifts the burden of tariffs and lets markets, businesses, and consumers do what they do best: allocate resources, generate wealth, and drive prosperity.

Perhaps a better term for this exercise would be a gedankenexperiment — a thought experiment of the sort often undertaken in physics and philosophy. If others indulge the fantasy that government intervention and the suppression of exchange makes everyone richer, I figure I can take my turn too. For now, it remains an exercise in imagination — but it is one well within the capacity of the current administration to make real.

On October 26, half of Argentina’s representatives and one-third of senators will face voters at the ballot box. This is, on its own, fortunately unexceptional. Indeed, Argentina has been a solid democracy since 1983, when the last generals left the presidential palace.

Nonetheless, these midterm elections represent an existential challenge for Argentina. They are, de facto, a referendum on the economic reforms of President Javier Milei. Milei, who was inaugurated on December 10, 2023, had flamboyantly promised to take a chainsaw to public spending, to tame an inflation rate nearing 300 percent per year, and to set the economy back on the path of growth. As realistic as he is idealistic, Milei promised 18 months of suffering and austerity measures to fix a country that had been ravaged by Perónism. Where does Argentina stand?

A Bit of History

Before looking at contemporary Argentina, it makes sense to offer a bit of historical context. Argentina was the forgotten backwater of the Spanish empire in the Americas; it lacked gold or a local population to be enslaved. After independence in 1816, Argentina suffered through a half-century of pendulum swings between dictatorships and civil wars — neither of which is favorable to economic growth. In 1860, Argentina adopted an almost verbatim translation of the US Constitution of 1787. Miraculous growth ensued. By 1910, Argentina was the eighth richest country in the world, a living laboratory for the economic theories of Adam Smith, Ludwig von Mises, F.A. Hayek, and Douglass North. Economic liberty, defense of contracts, freedoms of speech and religion — in sum, Argentina thrived under institutions that favored entrepreneurship and industrialization. Alas, Argentina didn’t quite have rule of law, but a ruling oligarchy with weak institutional safeguards. The first military coup came in 1930. There would be another 10 throughout the twentieth century, with a total of six military dictatorships (half the time, the military would simply evict the president and hold fresh elections).

The key factor for understanding the last century in Argentina is Perónism, a corporatism imported from Mussolini’s Italy, and given an Argentine flavor by Colonel (and future president) Juan Domingo Perón. Redistribution of wealth to buy friends and votes, populism, a corporatist balance of the country’s interest groups with an interventionist state as arbiter, five-year economic plans, and heavy regulation — these formed the new constitutional order. The eighth richest country in the world in 1910, Argentina suffered through a century of chronic hyperinflation, routine monetization of budget deficits, and economic crises — and fell to the rank of 68th richest country in the world today. Argentina has also garnered the dubious honor of being the IMF’s greatest debtor (it now owes $57 billion). Despite the obvious economic damage, the Perónist instinct dies hard; in the decade before Milei’s election, the Perónists doubled down on their policies. Intervention after intervention, regulation, redistribution, all took their toll. The poverty rate, which had fallen to 20 percent in 1993, hit a high of 58 percent before settling at 45 percent in 2023. The debt-spending was financed by printing money to feed friends and clients; hyperinflation, which had been tamed in the 1990s, returned, and rose to almost 300 percent per annum by 2023. Worst of all, the Perónists systematically destroyed the country’s institutional checks and balances.

Milei was elected in 2023, with a mandate to solve the economic consequences of Perónism. But the Perónists remain powerful: they hold 108 seats (of 257) in the lower house and 33 (of 72) in the Senate, along with 16 governor’s mansions (out of 23 provinces). This past September, the Perónist candidate won 47 percent of the votes in the Buenos Aires province gubernatorial election (against 33 percent for Milei’s party). To be sure, this province has long been a stronghold of Perónism… but this still represents a challenge to Milei’s reforms.

Halfway Through Milei’s Term, Where Is Argentina?

On December 10, 2023, Javier Milei inherited an economic and institutional disaster. He has — of course! — not been able fully to fix a century of interventionist damage in the span of two short years. But, 22 months into his presidency, where does Argentina stand?

Because he lacks a congressional majority, Milei has had to impose reforms by emergency decree. Such decrees, according to the Argentine constitution, are valid for one year, and must have the consent of one the two legislative chambers.

Milei was thus able to cut public spending, notably by reducing the number of cabinet agencies by half, from 18 to 9. By taking a chainsaw to government spending, Milei eliminated the budget deficit, a chronic feature of Perónist Argentina. Public debt, which had reached 155 percent of GDP in 2023, has now fallen to 83 percent.

Perónism’s fiscal profligacy had dire monetary consequences, because the budget deficit was routinely monetized by the central bank, which had effectively become an arm of the Treasury. Milei inherited an annual inflation rate of 294 percent which he has reduced to 34 percent (this would be unthinkable in the US, but is quite healthy by Argentine standards).

As a good economist (and economics professor), Milei has not focused exclusively on macroeconomics. He has also attacked microeconomic impediments, by removing the heaps of regulation that blocked growth and suffocated the economy. By emergency decree, Milei removed import controls and price controls. Notably, the real estate market was paralyzed by rent controls, mandatory three-year leases, and the inability to sign a lease using dollars (or any currency but the Argentine peso). One does not need a doctorate in economics to predict that the sad combination of regulation and hyperinflation would erode supply, as landlords faced the very real possibility of evaporated rents. Since Milei suspended rent controls, the price of rental housing in Argentina has fallen by 30 percent, and housing supply has increased by 212 percent.

Argentina’s risk premium has tumbled dramatically, and foreign investment has returned. After years of recession, economic growth is now at an enviable 6.3 percent. The middle class has surged, in two years, from 23 percent to 39 percent of the population. The 45 percent poverty rate Milei inherited from the Perónists temporarily rose to over 50 percent — Milei had indeed promised the pains of austerity — but has already fallen to 31 percent.

This is but a summary of Milei’s success.

There’s One More Thing

Unfortunately, there is one glaring omission in Milei’s reforms. 

He has allowed contracts to be signed in foreign currency and cryptocurrency. He has also imposed an amnesty for depositing the dollars that had been hidden in mattresses because of currency controls and the past freezing of dollar-denominated accounts. These are steps in the right direction. But he has not crossed the last Rubicon: the complete abolition of Argentina’s central bank — even though he had promised to wield his terrible swift chainsaw on it too. Closing the bank would have gotten rid of chronic hyperinflation, and opened the door to dollarization (which already exists de facto), or even currency competition, to replace the monetary cash cow.

Beyond the immediate economic benefit of taming and preventing hyperinflation, shutting down the central bank would represent the final nail in the coffin of Perónism. Indeed, all the good that Milei has brought to Argentina over the past two years could evaporate with one simple law or presidential decree if the Perónists return to power. Argentina would then relapse back into its perennial bad habits, with favors and votes purchased by redistribution, and budget deficits financed by the monetary printing press — in sum, a return to the predatory state of Perónism. Economist Emilio Ocampo (who had offered his services as the last president of Argentina’s central bank) explains that closing the central bank is the only method for Milei to show credible commitment to his reforms, and the only way to end the profligacy of Perónism.

These midterm elections are not merely a political footnote in the history of a troubled country. They are a veritable existential struggle between two forces. On one side, we have intervention, privilege, and a poverty that is as absurd as it is preventable. On the other, there is hope, progress, freedom, and prosperity.

Two federal judges admitted that members of their staff used artificial intelligence to prepare court orders over the summer that contained errors.

The admissions, which came from U.S. District Judge Julien Xavier Neals in New Jersey and U.S. District Judge Henry Wingate in Mississippi, came in response to an inquiry by Sen. Chuck Grassley, R-Iowa, who chairs the Senate Judiciary Committee.

Grassley described the recent court orders as ‘error-ridden.’

In letters released by Grassley’s office on Thursday, the judges said the rulings in the cases, which were not connected, did not go through their chambers’ usual review processes before they were released.

The judges both said they have since adopted measures to improve how rulings are reviewed before they are posted.

Neals said in his letter that a June 30 draft decision in a securities lawsuit ‘was released in error – human error – and withdrawn as soon as it was brought to the attention of my chambers.’

The judge said a law school intern used OpenAI’s ChatGPT to perform legal research without authorization or disclosure that he also said was contrary to the chamber’s policy and relevant law school policy.

‘My chamber’s policy prohibits the use of GenAI in the legal research for, or drafting of, opinions or orders,’ Neals wrote. ‘In the past, my policy was communicated verbally to chamber’s staff, including interns. That is no longer the case. I now have a written unequivocal policy that applies to all law clerks and interns.’

Wingate said in his letter that a law clerk used Perplexity ‘as a foundational drafting assistant to synthesize publicly available information on the docket,’ adding that releasing the July 20 draft decision ‘was a lapse in human oversight.’

‘This was a mistake. I have taken steps in my chambers to ensure this mistake will not happen again,’ the judge wrote.

Wingate had removed and replaced the original order in the civil rights lawsuit, declining at the time to give an explanation but saying it contained ‘clerical errors.’

Grassley had requested that the judges explain whether AI was used in the decisions after lawyers in the respective cases raised concerns about factual inaccuracies and other serious errors.

‘Honesty is always the best policy. I commend Judges Wingate and Neals for acknowledging their mistakes and I’m glad to hear they’re working to make sure this doesn’t happen again,’ Grassley said in a statement.

‘Each federal judge, and the judiciary as an institution, has an obligation to ensure the use of generative AI does not violate litigants’ rights or prevent fair treatment under the law,’ the senator continued. ‘The judicial branch needs to develop more decisive, meaningful and permanent AI policies and guidelines. We can’t allow laziness, apathy or overreliance on artificial assistance to upend the Judiciary’s commitment to integrity and factual accuracy. As always, my oversight will continue.’

Lawyers have also faced scrutiny from judges across the country over accusations of AI misuse in court filings. In response, judges have issued fines or other sanctions in several cases over the past few years.

Reuters contributed to this report.


This post appeared first on FOX NEWS

Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies.

Read on to learn what’s been driving these Canadian biotech firms.

1. Eupraxia Pharmaceuticals (TSX:EPRX)

Year-on-year gain: 141.23 percent
Market cap: C$410.85 million
Share price: C$8.25

Eupraxia Pharmaceuticals is developing clinical candidates that employ its DiffuSphere technology, which delivers treatments to the targeted tissues.

The company’s candidates are currently EP-104GI for eosinophilic esophagitis and EP-104IAR for knee osteoarthritis, and it is exploring the use of its technology for other active compounds as well.

Eupraxia added EP-104GI to its pipeline through its acquisition of EpiPharma Therapeutics in late 2023. The company has continued to advance the treatment through clinical trials in 2025 and released multiple rounds of positive data from its Phase 1b/2a trial cohorts.

In July, Eupraxia dosed its first patient after advancing its investigation to Phase 2b trials based on safety and efficacy data from the earlier Phase 2a patient cohorts. Top-line results from the Phase 2b study are anticipated in the second half of 2026.

In September, the company shared data from the highest-dose cohort of the still ongoing Phase 1b/2a trials, reporting that the group saw the largest improvements so far.

2. Bright Minds Biosciences (CSE:DRUG)

Year-on-year gain: 103.17 percent
Market cap: C$683.67 million
Share price: C$92.95

Bright Minds Biosciences is developing novel serotonin agonists targeting neurocircuit abnormalities linked to neuropsychiatric disorders and epilepsy, designing next-generation treatments that aim to retain the therapeutic benefits of psychedelics while minimizing side effects.

Its lead candidate, BMB-101, a selective 5-HT2C receptor agonist, has shown encouraging preclinical efficacy by stopping seizures in an epilepsy mouse model, evaluated jointly with Firefly Neuroscience (NASDAQ:AIFF).

The company’s stock surged nearly 1,500 percent in October 2024 following H. Lundbeck’s acquisition announcement of a competitor focused on similar targets. Strengthening its epilepsy expertise, Bright Minds expanded its scientific advisory board in early 2025 by adding five leaders in the field.

Ongoing clinical progress and strategic growth initiatives position Bright Minds as a promising contender in the neuropsychiatric treatment landscape.

3. Hemostemix (TSXV:HEM)

Year-on-year gain: 31.25 percent
Market cap: C$18.40 million
Share price: C$0.11

Hemostemix is a clinical-stage biotech company focused on developing autologous stem cell therapies, meaning the treatments use a patient’s own cells to theoretically enhance safety and efficacy.

Its main product, ACP-01, is an autologous cell therapy designed to promote tissue repair and regeneration in areas affected by diseases, including a range of heart diseases.

The company announced its first advanced sales orders for ACP-01 in Q1 2025 and has been working to expand internationally and attract new investment.

Hemostemix secured the regulatory green light for commercial sales in Florida after the state passed Senate Bill 1768. The bill creates a framework in which healthcare providers can administer stem cell therapies that had not yet been approved by the US Food and Drug Administration (FDA) but meet the bill’s guidelines.

The company now offers commercial ACP-01 treatments for ischemic pain in the state under the name VesCell, with sales forecasted to reach C$22.5 million in 2026. Operational plans target cash flow positivity by Q4 2026, supported by a growing physician network and commercial pipeline.

Additionally, Hemostemix is currently collaborating with Firefly Neuroscience on a Phase 1 clinical trial of ACP-01 for vascular dementia.

4. NervGen (TSXV:NGEN)

Year-on-year gain: 79.92 percent
Market cap: C$300.97 million
Share price: C$4.39

NervGen is a clinical-stage Canadian biotechnology company that focuses on developing innovative treatments to enable the nervous system to repair itself following damage from injury or disease.

The company’s core technology targets a mechanism that hinders nervous system repair. When the nervous system is damaged, chondroitin sulfate proteoglycans (CSPG) form a “scar.” Initially, CSPGs help contain damage, but their long-term interaction with the PTPσ receptor inhibits repair.

NervGen’s lead drug candidate, NVG-291, is designed to relieve these inhibitory effects to promote nervous system repair. It received fast-track designation from the US FDA.

NervGen is advancing NVG-291 in a Phase 1b/2a clinical trial for spinal cord injury (SCI) and reported positive data from the chronic cohort in June.

NVG-300, a newer preclinical candidate, is being evaluated for ischemic stroke and SCI.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com